image credit: Adobe Stock

Ayala Pharmaceuticals, Biosight Enter Definitive Merger Agreement

July 27, 2023

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, and BioSight Ltd., a pharmaceutical company developing therapeutics for hematological malignancies and disorders, entered into a definitive merger agreement pursuant to which Ayala will combine with Biosight in an all-stock transaction. The combined company will operate under the name Ayala Pharmaceuticals, Inc.

The company will work to advance a portfolio of oncology assets, with a primary focus on Ayala’s AL102, a once-daily, potent, selective, oral gamma-secretase inhibitor (GSI) and Biosight’s Aspacytarabine (BST-236). AL102 is currently being evaluated in the registrational RINGSIDE study in desmoid tumors.

Read More on Contract Pharma